15% de les nenes menors de quinze anys<\/strong>, per\u00f2 hem de tenir en compte que en pa\u00efsos amb gran pes poblacional com l’\u00cdndia o la Xina la vacuna encara est\u00e0 pendent d’implementaci\u00f3<\/em>\u201d. Pel que fa a Catalunya, les taxes de vacunaci\u00f3 s\u00f3n molt bones i ja han arribat a cobrir el 80% de les nenes.<\/p>\nLa recomanaci\u00f3 pel que fa al nombre de dosis tamb\u00e9 ha anat canviat a mesura que s’han tingut m\u00e9s dades. Aix\u00ed com en un inici la recomanaci\u00f3 eren tres dosis a l\u2019edat de 11-12 anys, ara ja s’ha establert que dues s\u00f3n suficients per aconseguir la immunitat. Fins i tot, ja s’est\u00e0 estudiant de reduir-ho a una sola dosi, estrat\u00e8gia que acaben d’aprovar al Regne Unit, i que podria afavorir la implantaci\u00f3 de la vacuna a tot el m\u00f3n.<\/p>\n
<\/p>\n
Millores en el cribratge<\/h3>\n
Fins ara el cribratge regular es feia a trav\u00e9s de citologies que inspeccionaven la possible pres\u00e8ncia de lesions precanceroses degudes a la infecci\u00f3 per VPH. A Catalunya es recomana que el cribratge s\u2019inici\u00ef als 25 anys d\u2019edat i es vagi fent peri\u00f2dicament fins els 65 anys.<\/p>\n
\u201cAra estan emergent proves moleculars, que detecten directament el material gen\u00e8tic del virus i que s\u00f3n molt m\u00e9s sensibles, el que permet diagnosticar m\u00e9s lesions i espaiar molt m\u00e9s els cribratges<\/em> -afegeix la Dra. Alemany<\/strong>-, a m\u00e9s, aquest tipus de proves permeten identificar el tipus de VPH, i aix\u00ed poder actuar en conseq\u00fc\u00e8ncia si es tracta d’un VPH amb alt risc oncog\u00e8nic<\/em>\u201d.<\/p>\nEl grup de recerca en infeccions i c\u00e0ncer de l’IDIBELL i de l’ICO est\u00e0 fent una prova pilot amb un dispositiu d\u2019automostra que permet recollir la mostra per a les proves moleculars a casa, i aix\u00ed evitar despla\u00e7aments. Per ara s’est\u00e0 valorant l’acceptaci\u00f3 de la poblaci\u00f3 a aquest nou dispositiu.<\/p>\n
<\/p>\n
<\/p>\n
L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\nL\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"El 2020 l’OMS va iniciar la campanya mundial per l’eliminaci\u00f3 del c\u00e0ncer de coll d’\u00fater a trav\u00e9s de la vacunaci\u00f3 del 90% de les nenes menors de quinze anys, el cribratge almenys dos cops a la vida del 70% de les dones, i el tractament adequat del 90% de les dones amb lesions precanceroses i c\u00e0ncer d’\u00fater.<\/p>\n","protected":false},"author":8,"featured_media":20784,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,337,454],"tags":[],"class_list":["post-20783","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-infeccions-i-cancer","category-p-depidemiologia-salut-publica-prevencio-del-cancer-i-cures-palliatives"],"publishpress_future_action":{"enabled":false,"date":"2025-03-02 13:35:02","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20783","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=20783"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20783\/revisions"}],"predecessor-version":[{"id":20785,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/20783\/revisions\/20785"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/20784"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=20783"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=20783"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=20783"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}